VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study

Reuters2025-12-11

VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study

VolitionRx Ltd. has announced the preprint availability of a new manuscript detailing a novel method, Capture-Seq™, and new biomarkers for cancer detection. The study involved a training cohort of 70 individuals, including 49 patients with breast, prostate, lung, or colorectal cancer. Results showed that the analysis of ultrashort transcription factor-bound DNA in plasma detected all cancer patients (100% sensitivity) and produced no false positives (100% specificity), including those with early-stage disease. These initial findings have not yet been validated in larger independent studies. The company also reported achieving a 180-fold enrichment of target DNA fragments and indicated that the technology may expand its Nu.Q® portfolio. The results have been made available in a preprint and have not yet been presented in a peer-reviewed forum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN44658) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590511820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590511820","market":"fut","top_or_hot":-1,"title":"VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VolitionRx Ltd. has announced the preprint availability of a new manuscript detailing a novel method, Capture-Seq™, and new biomarkers for cancer detection. The study involved a training cohort of 70 individuals, including 49 patients with breast, prostate, lung, or colorectal cancer. Results showed that the analysis of ultrashort transcription factor-bound DNA in plasma detected all cancer patients (100% sensitivity) and produced no false positives (100% specificity), including those with early-stage disease. These initial findings have not yet been validated in larger independent studies. The company also reported achieving a 180-fold enrichment of target DNA fragments and indicated that the technology may expand its <a href=\"https://laohu8.com/S/NU\">Nu</a>.Q® portfolio. The results have been made available in a preprint and have not yet been presented in a peer-reviewed forum.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN44658) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VolitionRx Ltd. has announced the preprint availability of a new manuscript detailing a novel method, Capture-Seq™, and new biomarkers for cancer detection. The study involved a training cohort of 70 individuals, including 49 patients with breast, prostate, lung, or colorectal cancer. Results showed that the analysis of ultrashort transcription factor-bound DNA in plasma detected all cancer patients (100% sensitivity) and produced no false positives (100% specificity), including those with early-stage disease. These initial findings have not yet been validated in larger independent studies. The company also reported achieving a 180-fold enrichment of target DNA fragments and indicated that the technology may expand its <a href=\"https://laohu8.com/S/NU\">Nu</a>.Q® portfolio. The results have been made available in a preprint and have not yet been presented in a peer-reviewed forum.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN44658) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VNRX","symbol_name":"VolitionRX Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL5D90Kg:1","article_id":"2590511820","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590511820","pubTimestamp":1765461669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"VolitionRx Ltd. has announced the preprint availability of a new manuscript detailing a novel method, Capture-Seq, and new biomarkers for cancer detection. The study involved a training cohort of 70 individuals, including 49 patients with breast, prostate, lung, or colorectal cancer. Results showed that the analysis of ultrashort transcription factor-bound DNA in plasma detected all cancer patients  and produced no false positives , including those with early-stage disease. These initial findings have not yet been validated in larger independent studies. The company also reported achieving a 180-fold enrichment of target DNA fragments and indicated that the technology may expand its Nu.Q portfolio. The results have been made available in a preprint and have not yet been presented in a peer-reviewed forum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VNRX":"VolitionRX Ltd","BK4198":"医疗保健用品"},"translate_title":"VolitionRX推出突破性液体活检方法，在早期研究中实现100%癌症检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNRX":0.9},"content_text":"VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study\n    \n\n        VolitionRx Ltd. has announced the preprint availability of a new manuscript detailing a novel method, Capture-Seq™, and new biomarkers for cancer detection. The study involved a training cohort of 70 individuals, including 49 patients with breast, prostate, lung, or colorectal cancer. Results showed that the analysis of ultrashort transcription factor-bound DNA in plasma detected all cancer patients (100% sensitivity) and produced no false positives (100% specificity), including those with early-stage disease. These initial findings have not yet been validated in larger independent studies. The company also reported achieving a 180-fold enrichment of target DNA fragments and indicated that the technology may expand its Nu.Q® portfolio. The results have been made available in a preprint and have not yet been presented in a peer-reviewed forum.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN44658) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590511820","isCrawlerRequest":true}